Literature DB >> 21987815

Direct activation of antigen-presenting cells is required for CD8+ T-cell priming and tumor vaccination.

Wolfgang Kratky1, Caetano Reis e Sousa, Annette Oxenius, Roman Spörri.   

Abstract

Successful priming of adaptive immune responses is crucially dependent on innate activation signals that convert resting antigen-presenting cells (APCs) into immunogenic ones. APCs expressing the relevant innate pattern recognition receptors can be directly activated by pathogen-associated molecular patterns (PAMPs) to become competent to prime T-cell responses. Alternatively, it has been suggested that APCs could be activated indirectly by proinflammatory mediators synthesized by PAMP-exposed cells. However, data obtained with CD4(+) T cells suggest that inflammatory signals often cannot substitute for direct pattern recognition in APC activation for the priming of T helper responses. To test whether the same is true for CD8(+) T cells, we studied cytotoxic T lymphocyte development in vitro and in mixed chimeric mice in which coexisting APCs can either present a preprocessed model antigen or directly recognize a given PAMP, but not both. We show that indirectly activated APCs promote antigen-specific proliferation of naïve CD8(+) T cells but fail to support their survival and cytotoxic T lymphocyte differentiation. Furthermore, CD8(+) T cells primed by indirectly activated APCs are unable to reject tumors. Thus, inflammation cannot substitute for direct recognition of single PAMPs in CD8(+) T-cell priming. These findings have important practical implications for vaccine design, indicating that adjuvants must be judiciously chosen to trigger the relevant pattern recognition receptors in APCs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21987815      PMCID: PMC3198339          DOI: 10.1073/pnas.1108945108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Natural adjuvants: endogenous activators of dendritic cells.

Authors:  S Gallucci; M Lolkema; P Matzinger
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

2.  Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells.

Authors:  M L Albert; M Jegathesan; R B Darnell
Journal:  Nat Immunol       Date:  2001-11       Impact factor: 25.606

3.  Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity.

Authors:  Andrea A Itano; Stephen J McSorley; R Lee Reinhardt; Benjamin D Ehst; Elizabeth Ingulli; Alexander Y Rudensky; Marc K Jenkins
Journal:  Immunity       Date:  2003-07       Impact factor: 31.745

4.  Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines.

Authors:  Alexander D Edwards; Sandra S Diebold; Emma M C Slack; Hideyuki Tomizawa; Hiroaki Hemmi; Tsuneyasu Kaisho; Shizuo Akira; Caetano Reis e Sousa
Journal:  Eur J Immunol       Date:  2003-04       Impact factor: 5.532

Review 5.  Found in translation: the human equivalent of mouse CD8+ dendritic cells.

Authors:  Jose A Villadangos; Ken Shortman
Journal:  J Exp Med       Date:  2010-05-31       Impact factor: 14.307

6.  Differential involvement of IFN-beta in Toll-like receptor-stimulated dendritic cell activation.

Authors:  Katsuaki Hoshino; Tsuneyasu Kaisho; Tomio Iwabe; Osamu Takeuchi; Shizuo Akira
Journal:  Int Immunol       Date:  2002-10       Impact factor: 4.823

7.  Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice.

Authors:  S M Santini; C Lapenta; M Logozzi; S Parlato; M Spada; T Di Pucchio; F Belardelli
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

8.  Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens.

Authors:  N Kadowaki; S Ho; S Antonenko; R W Malefyt; R A Kastelein; F Bazan; Y J Liu
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

9.  CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo.

Authors:  J M den Haan; S M Lehar; M J Bevan
Journal:  J Exp Med       Date:  2000-12-18       Impact factor: 14.307

10.  Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity.

Authors:  Mauritius Menges; Susanne Rössner; Constanze Voigtländer; Heike Schindler; Nicole A Kukutsch; Christian Bogdan; Klaus Erb; Gerold Schuler; Manfred B Lutz
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

View more
  33 in total

1.  Immune Surveillance by Natural IgM Is Required for Early Neoantigen Recognition and Initiation of Adaptive Immunity.

Authors:  Shaikh M Atif; Sophie L Gibbings; Elizabeth F Redente; Faye A Camp; Raul M Torres; Ross M Kedl; Peter M Henson; Claudia V Jakubzick
Journal:  Am J Respir Cell Mol Biol       Date:  2018-11       Impact factor: 6.914

Review 2.  Innate cellular immunity and xenotransplantation.

Authors:  Hui Wang; Yong-Guang Yang
Journal:  Curr Opin Organ Transplant       Date:  2012-04       Impact factor: 2.640

Review 3.  Cancer and innate immune system interactions: translational potentials for cancer immunotherapy.

Authors:  Yanan Liu; Gang Zeng
Journal:  J Immunother       Date:  2012-05       Impact factor: 4.456

Review 4.  Engineering nano- and microparticles to tune immunity.

Authors:  James J Moon; Bonnie Huang; Darrell J Irvine
Journal:  Adv Mater       Date:  2012-05-29       Impact factor: 30.849

5.  Yeast virus-derived stimulator of the innate immune system augments the efficacy of virus vector-based immunotherapy.

Authors:  Marie-Christine Claudepierre; Julie Hortelano; Emmanuelle Schaedler; Patricia Kleinpeter; Michel Geist; Christelle Remy-Ziller; Renée Brandely; Caroline Tosch; Laurence Laruelle; Anass Jawhari; Thierry Menguy; Jean-Baptiste Marchand; Pascale Romby; Patrick Schultz; Gunther Hartmann; Ronald Rooke; Jean-Yves Bonnefoy; Xavier Preville; Karola Rittner
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

Review 6.  Innate immune responses against Epstein Barr virus infection.

Authors:  Obinna Chijioke; Tarik Azzi; David Nadal; Christian Münz
Journal:  J Leukoc Biol       Date:  2013-06-28       Impact factor: 4.962

7.  Injectable cryogel-based whole-cell cancer vaccines.

Authors:  Sidi A Bencherif; R Warren Sands; Omar A Ali; Weiwei A Li; Sarah A Lewin; Thomas M Braschler; Ting-Yu Shih; Catia S Verbeke; Deen Bhatta; Glenn Dranoff; David J Mooney
Journal:  Nat Commun       Date:  2015-08-12       Impact factor: 14.919

Review 8.  Innate immune sensing of HIV-1 by dendritic cells.

Authors:  Jeremy Luban
Journal:  Cell Host Microbe       Date:  2012-10-18       Impact factor: 21.023

9.  Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation.

Authors:  Shazia Shabir; Baksho Kaul; Annette Pachnio; Gemma D Banham; Helen Smith; Sourabh Chand; Seema Jham; Lorraine Harper; Simon Ball; Afsar Rahbar; Cecilia Söderberg-Nauclér; Paul Moss; Richard Borrows
Journal:  J Am Soc Nephrol       Date:  2013-07-11       Impact factor: 10.121

10.  MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY.

Authors:  Therese Liechtenstein; Ines Dufait; Alessio Lanna; Karine Breckpot; David Escors
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.